Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rituximab shows promise for long-term control of rare blistering skin disease

NCT ID NCT03790293

Completed Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 80 patients with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers wanted to see how safe and effective rituximab (a drug that targets certain immune cells) is over the long term, compared to standard high-dose steroids. The goal was to check for serious side effects, relapse rates, and how the immune system changes years after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rituximab
What this could lead to
If successful, this could confirm that rituximab provides long-term remission with fewer side effects than standard steroids.
What could go wrong
This is a follow-up study, not a new treatment trial. It may show that benefits fade over time or that long-term immune suppression raises infection risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease pemphigus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

  • Ah-Hp Cochin

    Paris, 75006, France

  • Ap-Hm La Timone

    Marseille, 13385, France

  • Ap-Hp Avicenne

    Bobigny, 93000, France

  • Ap-Hp Bichat

    Paris, 75018, France

  • Ap-Hp Cochin

    Paris, 75014, France

  • Ap-Hp Henri Mondor

    Créteil, 94010, France

  • Ap-Hp Saint-Louis

    Paris, 75010, France

  • Ch Le Mans

    Le Mans, 72037, France

  • Chru Lille

    Lille, 59000, France

  • Chu Angers

    Angers, 49100, France

  • Chu Bordeaux

    Bordeaux, 33076, France

  • Chu Brest

    Brest, 29200, France

  • Chu Clermont-Ferrand

    Clermont-Ferrand, 63100, France

  • Chu Dijon

    Dijon, 21000, France

  • Chu Limoges

    Limoges, 87000, France

  • Chu Montpellier

    Montpellier, 34090, France

  • Chu Nantes

    Nantes, 44000, France

  • Chu Reims

    Reims, 51092, France

  • Chu Rennes

    Rennes, 35000, France

  • Chu Rouen

    Rouen, 76031, France

  • Chu Saint-Etienne

    Saint-Etienne, 42270, France

  • Chu Toulouse

    Toulouse, 31059, France

  • Chu Tours

    Tours, 37000, France

  • Hcl Ch Lyon Sud

    Lyon, 69310, France

  • Hcl Edouard Herriot

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.